This article is more than 5 years old. Information may no longer be current.

InSite, Merck, Pfizer to file patent infringement suit over generic version of AzaSite

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — InSite Vision will join Merck and Pfizer in filing a patent infringement lawsuit against a company seeking to market a generic version of AzaSite, InSite announced in a press release.

Sandoz filed an abbreviated new drug application with the U.S. Food and Drug Administration to market a generic version of AzaSite (azithromycin 1% ophthalmic solution) before the patents expire. InSite owns four U.S. patents regarding AzaSite, as well an exclusive license to a Pfizer-owned azithromycin patent, the release said.

AzaSite is currently marketed in the U.S. by Inspire, a wholly owned subsidiary of Merck. Inspire should have exclusive use of these patents in the U.S. until March 2019 under a license agreement between InSite and Inspire.

Merck will lead the lawsuit, but each company will be responsible for its own legal costs, the release said.